¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"fatty renal capsule"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • renal columns
    ÄáÆÏ±âµÕ
  • renal columns ³ª columnae renales
    ½ÅÁÖ(ãìñº).
  • renal compensation
    ½Åº¸»ó.
  • renal compensation
    ½Å¼º´ë»ó(ãìàõÓÛßÁ).
  • renal contusion
    ½ÅÁ»ó
  • renal corpuscle
    ½ÅÀå¼Òü, ½Å¼Òü(ãìá³ô÷).
  • renal corpuscle
    ÄáÆÏ¼Òü
  • renal corpuscle
    ½Å¼Òü
  • renal cortex
    ÄáÆÏ°ÑÁú
  • renal cortical adenoma
    ½ÅÇÇÁú¼±Á¾
  • renal cortical microcystic disease
    ½ÅÇÇÁú¹Ì¼¼³¶Á¾Áúȯ
  • renal cortical necrosis
    ½ÅÇÇÁú±«»ç(ãìù«òõ ÎÕÞÝ).
  • renal cortical necrosis
    ½ÅÇÇÁú±«»ç(ãìù«òõ ÎÕÞÝ)
  • renal counterbalance
    ½ÅÆòÇü(·®).
  • renal crest
    ÄáÆÏ´É¼±
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • cystic renal medullar
    ³¶¼º ½Å ¼öÁú(¡­ãìâÐòõ)
  • effective renal blood flow
    À¯È¿½ÅÇ÷·ù(·®)
  • effective renal blood flow =ERBF
    À¯È¿½ÅÇ÷·ù·®(êóüùãìúì×µÕá).
  • effective renal blood flow =ERBF
    À¯È¿½ÅÇ÷·ù·®.
  • effective renal plasma flow
    À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
  • effective renal plasma flow =ERPF
    À¯È¿½ÅÇ÷Àå·ù·®(êóüùãìúìíì×µÕá).
  • effective renal plasma flow =ERPF
    À¯È¿½ÅÇ÷Àå·ù·®.
  • end stage renal disease, ESRD
    ¸»±â½ÅÁúȯ
  • essential renal bleeding
    Ư¹ß¼º ½ÅÃâÇ÷.
  • gland of renal pelvis
    ÄáÆÏ±ò¶§±â»ù
  • greater renal calices<³ª> calix renalis major
    Å«(½ÅÀå)¼úÀÜ, ´ë½Å¹è(ÓÞãìÛÊ).
  • hemorrhagic fever with renal syndrome, HFRS
    ½ÅÁõÈÄ ÃâÇ÷¿­
  • hemorrhagic fever with renal syndrome, HFRS
    ½ÅÁõÈıº ÃâÇ÷¿­
  • hepato renal echo contrast
    °£ ½ÅÀå ¿¡ÄÚ ´ëÁ¶
  • hepato-renal echo contrast
    °£-½ÅÀå (ÊÜ-ãìíô) ¿¡ÄÚ ´ëÁ¶ (ÓßðÎ), °£-½ÅÀå (ÊÜ-ãì
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
LCP long-chain polysaturated [fatty acid]; lymphocyte cytosol polypeptide
MCFA medium-chain fatty acid; miniature centrifugal fast analyzer
NEFA nonesterified fatty acid
OHFA hydroxy fatty acid
PAPUFA physiologically active polyunsaturated fatty acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
FFA Plasma-free fatty acid
SFA Saturated fatty acid
SCFA Short Chain Fatty Acids
TFA Trans fatty acids
ufa Unsaturated fatty acid
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • renal uremia
    ½Å¼º ¿äµ¶Áõ
  • renal vascular injury
    ½Å Ç÷°ü ¼Õ»ó
  • renal vein
    ½Å Á¤¸Æ
  • renal vein thrombosis
    ½Å Á¤¸Æ Ç÷ÀüÁõ
  • renal venography
    ½Å Á¤¸Æ Á¶¿µ¼ú
  • renal venous pressure
    ½Å Á¤¸Æ¾Ð
  • renal vessel
    ½Å Ç÷°ü
  • selected renal arteriography
    ¼±ÅÃÀû ½Åµ¿¸Æ Á¶¿µ¹ý
    ´ëÅ𠵿¸Æ¿¡¼­ Ä«Å×Å͸¦ »ðÀÔÇØ Åõ½ÃÇÏ¿¡¼­ ¼±ÅÃÀûÀ¸·Î ½Åµ¿¸Æ¿¡ Á¶¿µÁ¦¸¦ ÁÖÀÔÇÏ´Â ¹æ¹ý.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
long-chain-fatty-acyl-glutamate deacylase <enzyme> Lca aminoacylase I almost specific to l-glutamate-containing lipoamino acids; lca aminoacylase II acts on fatty acyl amino acids with chain lengths between c11 and c16
Registry number: EC 3.5.1.55
Synonym: lca aminoacylase I, lca aminoacylase II, n-long chain acyl aminoacylase
(26 Jun 1999)
acute renal failure <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes.
Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect).
Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement.
(27 Sep 1997)
aminoaciduria, renal Impairment of renal tubular transport of amino acids.
(12 Dec 1998)
back-pressure renal atrophy <radiology> Caliectasis without obstruction, due to repeated episodes of obstruction, gradual loss of renal pyramids
(12 Dec 1998)
base of renal pyramid The outer broad part of a renal pyramid that lies next to the cortex.
Synonym: basis pyramidis renis.
(05 Mar 2000)
branchio-oto-renal syndrome <syndrome> An autosomal dominant disorder manifested by various combinations of preauricular pits, branchial fistulae or cysts, lacrimal duct stenosis, hearing loss, structural defects of the outer, middle, or inner ear, and renal dysplasia. Associated defects include asthenic habitus, long narrow facies, constricted palate, deep overbite, and myopia. Hearing loss may be due to mondini type cochlear defect and stapes fixation.
(12 Dec 1998)
capsular branches of renal artery <anatomy, artery> Branches arising from the renal artery outside of the kidney that are distributed to the renal capsule.
Synonym: rami capsulares arteriae renalis.
(05 Mar 2000)
captopril renal scan <radiology> In a kidney with a lesion in the afferent arteriole (e.g. Atherosclerotic plaque), reflex constriction of the efferent arteriole occurs through angiotensin system thus maintaining renal perfusion. ACE inhibition prevents constriction of efferent arteriole. Therefore, perfusion is decreased to a kidney with afferent lesions and the renal scan to looks WORSE. Bottom line: renal scans appear WORSE with captopril administration if there is a lesion in the afferent arteriole. See: renal artery stenosis
(12 Dec 1998)
carcinoma, renal cell Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural.
(12 Dec 1998)
renal <anatomy> Pertaining to the kidney, nephric.
(18 Nov 1997)
renal adenocarcinoma <radiology> Hypernephroma, renal cell carcinoma, arises from proximal collecting tubule, 10% bilateral adenocarcinoma types: papillary, alveolar, onchocytoma vascularity, 85% hypervascular (require pre-op embolization), 10% hypovascular (usually papillary type), 5% avascular associated with: tuberous sclerosis, von Hippel-Lindau syndrome see also: staging
(12 Dec 1998)
renal adenocarcinoma: staging <radiology> Typical presentation: Haematuria . . . . . 70% Fever . . . . . . . 16% Pain . . . . . . . . 50% Polycythemia . . . . 3% Palpable mass . . . 20% Anatomic staging (TNM): T1 Small tumour, kidney not enlarged T2 Large tumour, contained within renal capsule T3 Extension into perinephric fat or renal vein T4 Invasion of adjacent organs
(12 Dec 1998)
renal adenocarcinoma: vascularity <radiology> 85% hypervascular (require pre-op embolization), 10% hypovascular (usually the papillary type), 5% avascular also: 10% are bilateral
(12 Dec 1998)
renal agenesis <radiology> Associated with, duplicated vagina and/or uterus (mullerian duct anomaly), seminal vesicle cysts
(12 Dec 1998)
renal agents Drugs used for their effects on the kidneys' regulation of body fluid composition and volume. The most commonly used are the diuretics. Also included are drugs used for their antidiuretic and uricosuric actions, for their effects on the kidneys' clearance of other drugs, and for diagnosis of renal function.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á